Literature DB >> 16112632

Origins of endothelial and osteogenic cells in the subcutaneous collagen gel implant.

I Bilic-Curcic1, Z Kalajzic, L Wang, D W Rowe.   

Abstract

The interdependent relationship between vascular endothelial cells and osteoblasts during bone formation and fracture healing has been long appreciated. This paper reports a heterotopic implant model using FGF-2-expanded bone marrow stromal cells (BMSC) derived from Tie2eGFP (endothelial marker) and pOBCol3.6GFPcyan or topaz (early osteoblast marker) transgenic mice to appreciate the host/donor relationships of cells participating in the process of heterotopic bone formation. The study included various combinations of Tie2eGFP and pOBCol3.6GFPcyan and topaz transgenics as BMSC or whole bone marrow (WBM) donors and also as recipients. Rat tail collagen was used as a carrier of donor cells and implantation was done in lethally irradiated mice rescued with WBM injection. Development of ossicles in the implants was followed weekly during the 4- to 5-week long post-implantation period. By 4-5 weeks after total body irradiation (TBI) and implantation, a well-formed bone spicule had developed that was invested with bone marrow. Experiments showed absolute dominance of donor-derived cells in the formation of endothelial-lined vessels inside the implants as well as the marrow stromal-derived osteogenic cells. Host-derived fibroblasts and osteogenic cells were confined to the fibrous capsule surrounding the implant. In addition, cells lining the endosteal surface of newly formed marrow space carrying a pOBCol3.6GFP marker were observed that were contributed by WBM donor cells and the host. Thus, FGF-2-expanded BMSC appear to be a source of endothelial and osteogenic progenitor cells capable of eliciting heterotopic bone formation independent of cells from the host. This model should be useful for understanding the interactions between these two cell types that control osteogenic differentiation in vivo.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16112632     DOI: 10.1016/j.bone.2005.06.009

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  5 in total

1.  A Site-Specific Integrated Col2.3GFP Reporter Identifies Osteoblasts Within Mineralized Tissue Formed In Vivo by Human Embryonic Stem Cells.

Authors:  Xiaonan Xin; Xi Jiang; Liping Wang; Mary Louise Stover; Shuning Zhan; Jianping Huang; A Jon Goldberg; Yongxing Liu; Liisa Kuhn; Ernst J Reichenberger; David W Rowe; Alexander C Lichtler
Journal:  Stem Cells Transl Med       Date:  2014-08-13       Impact factor: 6.940

2.  Determination of the fate and contribution of ex vivo expanded human bone marrow stem and progenitor cells for bone formation by 2.3ColGFP.

Authors:  Dezhong Yin; Zhuo Wang; Qinghong Gao; Renuka Sundaresan; Chris Parrish; Qingfen Yang; Paul H Krebsbach; Alexander C Lichtler; David W Rowe; Janet Hock; Peng Liu
Journal:  Mol Ther       Date:  2009-07-14       Impact factor: 11.454

3.  Analysis of αSMA-labeled progenitor cell commitment identifies notch signaling as an important pathway in fracture healing.

Authors:  Brya G Matthews; Danka Grcevic; Liping Wang; Yusuke Hagiwara; Hrvoje Roguljic; Pujan Joshi; Dong-Guk Shin; Douglas J Adams; Ivo Kalajzic
Journal:  J Bone Miner Res       Date:  2014       Impact factor: 6.741

4.  Bone formation during distraction osteogenesis is dependent on both VEGFR1 and VEGFR2 signaling.

Authors:  Kimberly A Jacobsen; Zainab S Al-Aql; Chao Wan; Jennifer L Fitch; Stephanie N Stapleton; Zachary D Mason; Robert M Cole; Shawn R Gilbert; Thomas L Clemens; Elise F Morgan; Thomas A Einhorn; Louis C Gerstenfeld
Journal:  J Bone Miner Res       Date:  2008-05       Impact factor: 6.741

5.  Comparative study of three types of mesenchymal stem cell to differentiate into pancreatic β-like cells in vitro.

Authors:  Yunfang Mo; Zejian Wang; Jian Gao; Yan Yan; Huaijuan Ren; Fengli Zhang; Nianmin Qi; Yantian Chen
Journal:  Exp Ther Med       Date:  2021-07-01       Impact factor: 2.447

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.